AVEO Pharmaceuticals

We are united in our efforts to provide patients with reasons to believe that they can receive effective treatments while carrying on with their daily living.

AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.

AVEO’s strategy is to focus its resources toward development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO’s lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC.

AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck squamous cell carcinoma (HNSCC), pancreatic cancer and acute myeloid leukemia, and expects to make a go/no-go decision on the initiation of a pivotal Phase 3 study of ficlatuzumab in HPV negative HNSCC following feedback from the FDA. AVEO’s pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia.

AVEO’s earlier stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.

Life at AVEO

AVEO Selected as a Top Ten Therapeutics Company 2022

“AVEO Oncology is a patient focused, science driven company which fosters a collaborative work environment in the pursuit of our mission to provide the oncology community with improved treatment options for patients with cancer.  

While doing so, we believe in providing dedicated individuals with opportunities for professional development through broad exposure to a variety of disciplines, an open door policy at all levels, and an enjoyable and engaging work environment.”

- Michael P. Bailey – President & CEO

We are always looking for enthusiastic and talented individuals who share our passion for science and making an impact on lives of patients and on our community. We welcome your expertise, insight and enthusiasm to help us develop and commercialize novel drugs that bring new hope to cancer patients.